Current Medical Treatment of Patients with Non-Colorectal Liver Metastases: Primary Tumor Breast Cancer.
Current Medical Treatment of Patients with Non-Colorectal Liver Metastases: Primary Tumor Breast Cancer.
复制标题
DOI：
10.1159/000441961
复制
发表时间：
2015-12
期刊：
影响因子：
--
通讯作者：
Kolberg HC
中科院分区：
文献类型：
--
作者：
Liedtke C;Kolberg HC
（转移性）乳腺癌是一种异质实体，其中每种疾病亚型都需要个体化的系统治疗方法。我们回顾了目前有关乳腺癌全身治疗的可用数据，并对历史和当前的治疗方法进行了回顾，引用的出版物涵盖了从 1896 年到上一届 ASCO 2015 的时间跨度。转移性乳腺癌的全身治疗可能包括化疗、内分泌治疗和靶向治疗（例如基于抗体的方法）。根据患者的乳腺癌亚型，这些药物可以单独或组合使用。因此，疾病表型的表征是必要的，并且可能包括转移部位的活检。新的治疗方法包括免疫疗法以及 PARP、PI3K 和 CDK 4/6 抑制剂，目前正在临床试验中进行研究。转移性乳腺癌的系统治疗需要复杂且个体化的治疗方法，最好在跨学科环境中提供。
(Metastatic) breast cancer is a heterogeneous entity in which every disease subtype requires an individualized systemic treatment approach. We reviewed the currently available data regarding systemic therapy of breast cancer and present a review of historical and current treatment approaches, with the publications cited covering a time span from 1896 to the last ASCO 2015. Systemic therapy of metastatic breast cancer may include chemotherapy, endocrine therapy, and targeted therapies (e.g. antibody-based approaches). Based on the patient's breast cancer subtype, these agents may be employed alone or in combination. Therefore, characterization of the phenotype of the disease is necessary and may include biopsy of the metastatic site. Novel therapeutic approaches include immunologic therapies as well as PARP, PI3K and CDK 4/6 inhibitors, which are currently under investigation in clinical trials. Systemic therapy of metastatic breast cancer requires complex and individualized treatment approaches that are best offered in an interdisciplinary setting.